Sun Pharma, Philogen Advance Nidlegy After Mixed Fibromun Trial Results

Sun Pharmaceutical Industries Limited ( (IN:SUNPHARMA) ) has issued an update.

Sun Pharmaceutical Industries, in collaboration with partner Philogen, reported mixed clinical outcomes for its oncology candidate Fibromun, with Phase II trials in last-line soft tissue sarcoma and second-line glioblastoma failing to meet primary endpoints, though a survival benefit emerged in a glioblastoma subgroup with limited prior alkylating exposure. The partners are pressing ahead with first-line glioblastoma and soft tissue sarcoma programs, including the GLIOSUN and GLIOSTELLA trials and a planned Phase III FIBROSARC-2 study, reflecting continued investment despite clinical setbacks.

For Nidlegy, a biopharmaceutical therapy for skin cancers, Sun Pharma and Philogen are resetting their European melanoma strategy with a new regulatory submission and advancing a Phase III trial in locally advanced melanoma across the U.S. and Europe. Strong Phase II results in basal cell and cutaneous squamous cell carcinomas are underpinning the launch of multiple registrational studies in both melanoma and non-melanoma skin cancers, potentially strengthening Sun Pharma’s oncology franchise if forthcoming late-stage trials and regulatory interactions remain positive.

More about Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is a major Indian pharmaceutical company focused on developing and marketing branded and generic medicines, including complex therapies in oncology and dermatology. Through partnerships such as its collaboration with Philogen, the company is building a pipeline of biologics and biopharmaceuticals targeting cancers with high unmet medical need in global markets.

Average Trading Volume: 133,252

Technical Sentiment Signal: Strong Buy

Current Market Cap: 4306.3B INR

See more insights into SUNPHARMA stock on TipRanks’ Stock Analysis page.